TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 67.32%의 증가율을 기록했습니다.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 69.30M에 달합니다.
과대 평가된
회사의 최신 PE은 -1.54로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 33.40M주이며, 전 분기 대비 17.06% 감소했습니다.
더 뱅가드가 보유
스타 투자자 더 뱅가드이(가) 이 주식 1.91M주를 보유하고 있습니다.